dSMAX-3

ATP7A | 2010

What Is dSMAX-3?

dSMAX-3 is a type of CMT caused by X-linked recessive mutations in the ATP7A gene. This gene provides instructions for making a copper-transporting protein essential to the normal function of motor nerve cells. Mutations in the ATP7A gene disrupt this function, leading to impaired nerve signal transmission.

dSMAX-3 is X-linked recessive. This means the gene lives on the X chromosome, and in people with two X chromosomes (chromosomal females), a mutation in both copies of the gene is needed to cause dSMAX-3. For individuals with one X and one Y chromosome (chromosomal males), a mutation in their single copy of the gene is sufficient to cause dSMAX-3.

Clinical Features

The age of symptom onset in dSMAX-3 is variable, ranging from childhood to adulthood. As a motor neuropathy, dSMAX-3 primarily affects the most distal points, with weakness and atrophy of the feet and hands, and little to no involvement of the sensory nerves. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

dSMAX-3 symptoms may include:

  • Weakness and atrophy in the feet and lower legs
  • Foot drop
  • Reduced or absent reflexes
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

dSMAX-3 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
dSMAX-3

Classification
dSMA

Neuropathy Type
Axonal

Inheritance Pattern
X-linked recessive

Genetic Context

HGNC-Approved Gene Symbol
ATP7A

Gene Full Name
ATPase copper transporting alpha

Chromosome
Xq21.1

Zygosity of Responsible Variant
Hemizygous (Male)/Homozygous (Female)

Variant Mechanism

Loss of Function (LoF)

Details

Mechanistic basis:
Hypomorphic

Confidence:
Medium

Prediction:
The published evidence supports a loss-of-function mechanism for dSMAX-3: the two ATP7A alleles characterized in X-linked distal hereditary motor neuropathy, p.Thr994Ile and p.Pro1386Ser, retain copper-transport capacity but mislocalize the ATPase, impairing its copper-responsive movement between the trans-Golgi network and the plasma membrane. Hemizygous males have no second ATP7A to compensate, and restored wild-type protein is predicted to rescue a partial, trafficking-level deficit rather than the near-complete deficiency of Menkes disease.

Rationale:
The ATP7A allelic series anchors this reading: severe truncating variants produce Menkes disease, milder alleles produce occipital horn syndrome, and these two trafficking-defective missense variants sit at the mild end, with serum copper and ceruloplasmin unremarkable. Whether the motor phenotype follows from that residual deficit alone or from a neuron-specific trafficking requirement is unsettled, which is why confidence stops at medium.

ClinVar Pathogenic Variants

View ATP7A ClinVar Variants

dSMAX-3 OMIM Entry

dSMAX-3 OMIM

ATP7A OMIM Entry

ATP7A OMIM

More Info

dSMAX-3 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Missense Mutations in the Copper Transporter Gene ATP7A Cause X-Linked Distal Hereditary Motor Neuropathy

Authors

Kennerson, M. L., Nicholson, G. A., Kaler, S. G., Kowalski, B., Mercer, J. F., Tang, J., Llanos, R. M., Chu, S., Takata, R. I., Speck-Martins, C. E., Baets, J., Almeida-Souza, L., Fischer, D., Timmerman, V., Taylor, P. E., Scherer, S. S., Ferguson, T. A., Bird, T. D., De Jonghe, P., Feely, S. M., … Garbern, J. Y.

Publication Date
March 12, 2010

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


A Name That Does Too Much Work

Jean-Martin Charcot's name appears throughout medicine, but nowhere does it create more confusion than in the foot. Learn why the CMT foot and Charcot neuroarthropathy, also known as Charcot foot, share a name yet differ in how they develop, appear, and are managed.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.